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The transcription factor NF-E2-related factor 2 (Nrf2) is a master regulator of a genetic program, termed the phase 2 response,
that controls redox homeostasis and participates in multiple aspects of physiology and pathology. Nrf2 protein stability is regu-
lated by two E3 ubiquitin ligase adaptors, Keap1 and -TrCP, the latter of which was only recently reported. Here, two-dimen-
sional (2D) gel electrophoresis and site-directed mutagenesis allowed us to identify two serines of Nrf2 that are phosphorylated
by glycogen synthase kinase 3 (GSK-3) in the sequence DSGISL. Nuclear magnetic resonance studies defined key residues of
this phosphosequence involved in docking to theWD40 propeller of -TrCP, through electrostatic and hydrophobic interac-
tions. We also identified three arginine residues of -TrCP that participate in Nrf2 docking. Intraperitoneal injection of the
GSK-3 inhibitor SB216763 led to increasedNrf2 andheme oxygenase-1 levels in liver and hippocampus.Moreover,micewith hip-
pocampal absence ofGSK-3 exhibited increased levels ofNrf2 and phase 2 gene products, reduced glutathione, and decreased levels
of carbonylated proteins andmalondialdehyde. This study establishes the structural parameters of the interaction ofNrf2with the
GSK-3/-TrCP axis and its functional relevance in the regulation ofNrf2 by the signaling pathways that impinge onGSK-3.
Organisms have developed complex defense mechanisms tocontrol damage produced by harmful endogenous and exog-
enous agents. In recent years it has become apparent that the tran-
scription factor NF-E2-related factor 2 (Nrf2) plays a central role
in controlling both intrinsic and inducible resistance to oxidants
and electrophiles (43). Nrf2 was initially reported as a cap’n’collar
basic-region leucine zipper transcription factor that controls the
expression of drug metabolism genes that contain antioxidant re-
sponse elements (ARE) in their promoter regions (15, 48). Nrf2 is
now considered a master regulator of redox homeostasis, which
controls the expression of over 100 genes involved in defense
against reactive oxygen species and electrophiles.
In common with other transcription factors involved in
protection against stress, such as hypoxia-inducible factor 1
(HIF1), heat shock factor (HSF), ATF4, and NF-B, basal activ-
ity of Nrf2 is restricted to low levels. Indeed, high constitutive Nrf2
activity has been observed only in some tumors, where it is asso-
ciated with increased cell proliferation and resistance to chemo-
therapeutic drugs. Thus, in a proportion of lung cancers, high
Nrf2 activity is due to somatic mutations that enable this factor to
evade, at least partially, degradation through the ubiquitin-pro-
teasome pathway (13, 46).
Nrf2 is principally controlled through regulation of protein
turnover by the ubiquitin-proteasome system, exhibiting a half-
life of about 30 min. More than 100 different protein adaptors
mediate the interaction of a few E3 ubiquitin ligases with their
substrates. These adaptors confer selectivity to the process by their
ability to recognize unique sequences in the target protein that are
required for degradation (i.e., degrons). Many of these cis-acting
sequences contain several Ser or Thr residues that need to be phos-
phorylated in order to create a phosphodegron that can then be
recognized by the adaptor E3 ligase protein. In other cases, the
phosphorylated Ser or Thr residues may be replaced with nega-
tively charged amino acids that form a permanent docking site for
their appropriate E3 ligase adaptor protein. The Nrf2 protein ap-
pears to be controlled through both degron and phosphodegron
sequences. It is constitutively recognized by the substrate adaptor
Keap1 in its N-terminal Neh2 domain and presented for Cul3
(cullin-3)-based E3 ligase ubiquitination and proteasomal degra-
dation (6, 10, 21, 22, 26, 28, 47, 54). Keap1 is inhibited by thiol-
reactive compounds, and upon exposure to such stressors, Keap1-
mediated ubiquitination of Nrf2 by Cul3 ceases to occur. While
this model explains how Nrf2 is upregulated by soft electrophiles
other regulatory mechanisms must exist because Nrf2 is abundant
in metabolically active tissues regardless of Keap1 levels (4), and it
is influenced by growth factor signaling through a Keap1-inde-
pendent mechanism.
Recently we reported the existence of a previously unrecog-
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nized phosphodegron in Nrf2 that requires the concerted action
of glycogen synthase kinase 3 (GSK-3) isoform  or  and the E3
ligase adaptor -transducin repeat-containing protein (38).
(Note that there are two mammalian -TrCP paralogues,
-TrCP1 and -TrCP2, which possess similar properties. In this
paper we employ the general term -TrCP unless specific experi-
mental details are described.) In particular, we provided evidence
that GSK-3 or -might phosphorylate Nrf2 somewhere within a
cluster of Ser residues in the Neh6 domain of Nrf2 that overlaps
with a putative destruction motif for -TrCP. However, the spe-
cific residues that are phosphorylated by GSK-3 or the residues
that interact with-TrCP have not been identified. Also, the func-
tional consequences of this degradation pathway are not known.
In the present study, we characterized the Ser residues that are
phosphorylated by GSK-3 to create the -TrCP-dependent
phosphodegron. By using a combination of transfer nuclear mag-
netic resonance (NMR) and docking experiments (37), we have
identified the phosphorylated residues of Nrf2 that contact spe-
cific amino acids that comprise the binding pocket in the WD40
propeller of -TrCP. Finally, we show that the expression of Nrf2
target genes is increased in the hippocampi of mice that lack
GSK-3.
MATERIALS AND METHODS
Neuron-specific GSK-3 knockout mice. Mice with postnatal neuronal
deficiency of GSK-3 were generated by the Cre/lox system as described
previously (18). Transgenic mice with the GSK-3 gene flanked by loxP
sites were crossed with mice expressing Cre recombinase under the Thy1
gene promoter. Mice with two floxed GSK-3 alleles but not expressing
Cre recombinase (Cre mice) were used as controls for the double-trans-
genic mice that express Cre recombinase (Cre mice) and that lack both
GSK-3 alleles postnatally and only in neurons (18). All experiments were
approved by the KU Leuven ethical commission, according to institu-
tional Belgian and European guidelines (European Council Directives
86/609/EEC and 2003/65/EC). Animals were anesthetized with 8 mg/kg
ketamine and 1.2 mg/kg xylazine and, depending on the experiment, per-
fused with 4% paraformaldehyde for immunohistochemistry analysis or
sacrificed by cervical dislocation, and the hippocampus was rapidly frozen
at 80°C for RNA and protein analysis.
Drug administration and tissue processing. Three-month-old male
C57BL/6 mice were intraperitoneally injected with five doses of 10 mg/kg
SB216763 dissolved in 10% dimethyl sulfoxide (DMSO) in saline buffer at
1-hour intervals. The control group was injected with vehicle (10%
DMSO in saline) using the same schedule. We also included positive-
control mice injected with a single dose of 50 mg/kg sulforaphane (SFN)
for 1 h. Hippocampi and livers from both groups were dissected after 6 h
and processed for immunoblot analysis. Briefly, 100 mg of liver was ho-
mogenized using a Polytron homogenizer in 0.4 ml of cold lysis buffer (50
mM HEPES [pH 7.4], 1% Triton X-100, 50 mM NaPPi, 0.1 M NaF, 10
mM EDTA, 10 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, and 1
g/ml leupeptin). After 30 min in ice, the samples were centrifuged at
80,000 g and 4°C during 1 h. Supernatants were analyzed by immunoblot-
ting. Hippocampi were homogenized in 0.2 ml of cold radioimmunopre-
cipitation assay (RIPA) buffer (25 mM Tris-HCl [pH 7.6], 150 mM NaCl,
1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 0.1% sodium dodecyl
sulfate [SDS], 0.1 M NaF, 10 mM EDTA, 10 mM Na3VO4, 1 mM phenyl-
methylsulfonyl fluoride, and 1 g/ml leupeptin). Samples were sonicated
after addition of loading buffer containing 2% SDS.
Reduced and oxidized glutathione levels. Reduced glutathione
(GSH) levels were measured using a fluorometric method according to
reference 11. Hippocampal tissue samples were homogenized in 1 ml
EDTA-phosphate buffer (pH 8.0) with 300 l HPO3 (25%) and centri-
fuged at 3,000  g for 15 min. Afterwards, 500 l of supernatant was
derivatized with 100 l of o-phthalaldehyde. Mixtures were then incu-
bated for 20 min at 25°C, and the amount of GSH was calculated by
measuring the corresponding fluorescent signal in a Synergy HT fluorom-
eter (Bio-Tek) at wavelengths of 350 nm (excitation) and 420 nm (emis-
sion). Total glutathione was evaluated by performing a reduction step of
oxidized glutathione (GSSG). Briefly, 500 l of sample was mixed with
100 l of 25 mM dithiothreitol and incubated for 30 min at 40°C. The
samples were centrifuged (5,000 g, 10 min), and supernatants were used
for derivatization. The GSSG concentration was obtained by subtracting
experimental-GSH from whole-GSH values after the reduction step. Data
were corrected for protein content.
Protein carbonyl content.As previously described (31), hippocampal
homogenates were incubated with 10% streptomycin sulfate to remove
nucleic acids and centrifuged at 6,000  g (4°C, 20 min). Supernatants
were treated with 10 mM 2,4-dinitrophenylhydrazine (DNPH, in 2.5 M
HCl) for 1 h at 25°C. After addition of 20% trichloroacetic acid, samples
were centrifuged (3,000 g, 4°C) for 10 min. Pellets were dissolved with
1 M guanidine hydrochloride (in phosphate buffer, pH 8.0) and centri-
fuged (5,000  g, 4°C) for 5 min. Absorbance was measured in a spec-
trometer at 370 nm. Protein carbonyl content is expressed as nmol
DNPH/mg protein using the molar absorption coefficient of DNPH
(22,000 M1 cm1).
Malondialdehydedetermination.Lipid peroxidation was determined as
the formation of thiobarbituric acid-reactive substances (TBA-RS), ac-
cording to a previous report (12). Three hundred microliters of hip-
pocampal homogenates was added to 500l of TBA reagent (0.375 g TBA,
7.5 g trichloroacetic acid, and 2.54 ml HCl) and incubated at 100°C for 30
min. A pink chromophore was produced in samples in direct relation to
the amount of peroxidized products. Samples were then kept in ice for 5
min and centrifuged at 3,000  g for 15 min. The optical density of the
supernatants was measured in a spectrometer at 532 nm. The amount of
TBA-RS (mostly malondialdehyde [MDA]) was calculated by interpola-
tion of values in a constructed MDA standard curve with 1,1,3,3-tetrame-
toxypropane, and results were expressed as nanomoles of MDA per mg of
protein.
Cell culture and reagents.Human embryonic kidney 293T (HEK293T)
cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum and 80 g/ml gentamicin. Transient
transfections were performed with calcium phosphate, using reagents from
Sigma-Aldrich (Madrid, Spain) or with TransFectin lipid reagent from Bio-
Rad (Hercules, CA). SB216763 and MG132 were from Sigma-Aldrich. Sul-
foraphane (SFN) was from LKT Laboratories (Saint Paul, MN).
Transient transfection of MEFs and luciferase assay. Immortalized
mouse embryo fibroblasts (MEFs) from Nrf2-null mice (derived from
Nrf2 knockout mice initially provided by Masayuki Yamamoto, Tohoku
University, Sendai, Japan [15]) were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 15% bovine growth serum (HyClone,
Waltham, MA) and 100 U/ml penicillin plus 0.1 mg/ml streptomycin.
One day before transfection, immortalized Nrf2-null MEFs were seeded at
80% confluence in 24-well plates. Transient transfection was performed
with the GenJet in vitro DNA transfection reagent (Signagen Laborato-
ries, Gaithersburg, MD) following the manufacturer’s instructions. Ex-
pression vectors were pTK-Renilla (Promega), ARE-Luc (which was de-
scribed previously [27]), and the indicated Nrf2 and GSK-3 mutant
versions in Fig. 5B. After a 48-h recovery from transfection, the cells were
lysed and assayed for luciferase activity with a dual-luciferase assay system
(Promega). Relative light units were measured in a GloMax 96 microplate
luminometer with dual injectors (Promega). Light units were normalized
with Nrf2 mutant expression levels using a quantitative reverse transcrip-
tion-PCR (qRT-PCR) method and the primers 5=-TGA ATA CTC TCT
GCA GCA AA-3= and 5=-GAG GGT TAG GGA TAG GCT TA-3=.
Plasmids. The expression vectors pcDNA3.1-mNrf2-V5/HisB and
pcDNA3.1-mNrf2ETGE-V5/HisB were previously described (29). Vec-
tors pCGN-HA-GSK-39 and pCGN-HA-GSK-3Y216F were provided
by Akira Kikuchi (Department of Biochemistry, Faculty of Medicine, Hir-
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oshima University). Conditions of active GSK-3 were obtained by trans-
fection of the constitutively active mutant GSK-39, which lacks the first
9 amino-terminal residues. Conditions of GSK-3 inactivation were
achieved by transfection of the hypomorphic Y216F mutant (7) and in-
cubation with the GSK-3 inhibitor SB216763 (10 M, 3 h). A plasmid
encoding -TrCPFbox (pcDNA3-TrCPFbox-HA) was provided by
Serge Y. Fuchs (Department of Animal Biology, University of Pennsylva-
nia, Philadelphia, PA). An expression construct encoding -TrCP1
(pcDNA3-Flag--TrCP1) was provided by Tomoki Chiba (Department
of Molecular Biology, University of Tsukuba, Japan). Chimeric construct
1 of the pEYFP-mNrf2-V5 series was generated as described in reference
42 for plasmid pEYFP-Nrf2-V5. The other chimeras were generated using
1 as the template with a GC-rich PCR system (Roche Applied Science,
Basel, Switzerland). N-terminal deletions were generated with a common
reverse primer: 5=-TCAGAAGCCATAGAGCCCACCGCAT-3=. The for-
ward primers were as follows:2, 5=-TAACGGATCCTTCATAGCAGAG
CCCAGTGAC-3=; 3, 5=-TAACGGATCCAAAGCTTTCAACCCGAAG
CAC-3=; 4, 5=-TAACGGATCCCAGAACGGCCCTAAAGCACAG-3=,
and 5, 5=-TAACGGATCCAAAAATCATTAACCTCCCTGTT-3=. The
amplified fragments were digested with BamHI (underlined) and PmeI
and cloned in pEYFP-CI between the BglII and SmaI sites. pcDNA3.1-
mNrf2ETGE 6S/6A-V5/HisB containing the mutations S335A, S338A,
S342A, S347A, S351A, and S355A was previously described (38).
Plasmids encoding EYFP-mNrf2(317–372)-V5 and EYFP-
mNrf2(317–372) 6S/6A-V5 were generated using the primers 5=-TAACAG
ATCTGGTAAGCCTATCCCTAACCCTCTCCTC-3= (forward) and 5=-T
AACAGATCTATCTAGCTCCTCCATTTCCGAGTCACT-3= (reverse)
and pEYFP-mNrf2-V5 and pEYFP-mNrf26S/6A-V5 as templates, respec-
tively. Underlined HindIII sites were included in all primers to allow the
religation of the PCR product. Mutant mNrf2 and -TrCP constructs
were generated using GeneTailor site-directed mutagenesis system
(Invitrogen, Carlsbad, CA), and the primers are shown in Table SA in the
supplemental material. All sequences were verified by automated se-
quencing. pcDNA3.1-mNrf22S/2A-V5/HisB, pcDNA3.1-mNrf22SP/2AP-
V5/HisB, and pcDNA3.1-mNrf24S/4A-V5/HisB were generated by replac-
ing the fragment between two HindIII sites with the corresponding
portions of pcDNA3.1-mNrf2ETGE-V5/HisB.
Immunoblotting. The primary antibodies used were anti-V5 and anti-
-TrCP (Invitrogen), antihemagglutinin (anti-HA) (Covance, Berkeley,
CA), anti-GFP and anti-Flag (Sigma-Aldrich), anti-GSK-3 (Cell Signaling,
Beverly, MA), anti-Keap1 and-actin (Santa Cruz Biotechnology), sc-33569
and sc-1616 (Santa Cruz, Delaware, CA), anti-GSTM5 and anti-mouse Nrf2
(made in the Hayes laboratory), anti-GCLM and anti-GCLC (kind gifts from
Terrance Kavanagh, University of Washington), anti-human Nrf2 (Abgent,
San Diego, CA) anti-HO-1 (made in the Cuadrado laboratory), and anti-
NQO1 (Abcam, Cambridge, United Kingdom). Cell lysates were resolved by
SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to Immo-
bilon-P membranes (Millipore, Billerica, MA). These membranes were ana-
lyzed using the appropriate primary antibodies and peroxidase-conjugated
secondary antibodies. Proteins were detected by enhanced chemilumines-
cence (GE Healthcare, Buckinghamshire, United Kingdom).
Coimmunoprecipitation. Assays were performed as indicated else-
where (38). The samples were resolved by SDS-PAGE and immuno-
blotted. Mouse IgG TrueBlot (eBiosciences, San Diego, CA) was used as
the peroxidase-conjugated secondary antibody (1:10,000 dilution) to
avoid interference with the 55-kDa heavy and 23-kDa light chains of the
immunoprecipitating antibody.
2D-PAGE.Assays with lambda phosphatase (	PPase) and 2D gel elec-
trophoresis were performed as described in reference 40. Reagents for
2D-PAGE were supplied by PlusOne-GE Healthcare.
In vitro kinase assays. In vitro phosphorylation was performed using
immunocomplexes with V5-tagged EYFP-Neh6 Nrf2 versions, which
were immunoprecipitated with anti-V5 antibodies from transiently trans-
fected HEK293T cells. In all cases, the kinase assays were performed using
5 ng of active recombinant GSK-3 (Millipore) per reaction and 5 Ci of
[
-32P]ATP in 25l of reaction buffer (10 mM MgCl2, 100M ATP in 40
mM MOPS [pH 7.0], and 1 mM EDTA) for 20 min at 30°C with contin-
uous shaking. Kinase reaction products were resolved by SDS-PAGE,
transferred to Immobilon-P membranes, and subjected to autoradiogra-
phy or immunoblotted.
Peptide synthesis.The Nrf2 peptide with residues 333 to 362 from the
human sequence (4P-hNrf2) with phosphorylated serines at positions
344, 347, 351, and 356 was purchased from Invitrogen. The Nrf2 peptide
comprising residues 333 to 359 (2P-hNrf2) with phosphorylated serines
at positions 344 and 347 was purchased from JPT Innovative Peptide
Solutions (Berlin, Germany). The purity of both peptides was higher than
95%, as determined by high-pressure liquid chromatography (HPLC).
Both peptides were N acetylated and C amidated at their respective ter-
mini.
Purification of theWDrepeat region fromhumanprotein-TrCP1
fused to themaltose-bindingprotein (MBP).The method of purification
of MBP–-TrCP was previously described (36). Following this protocol,
the final yield of purified MBP--TrCP was 1.3 mg/liter. This amount of
purified recombinant protein was used to prepare the NMR samples.
NMR spectroscopy. NMR spectroscopy experiments were run at
500.13 MHz for 1H on a Bruker Avance 500 spectrometer with a Linux PC
workstation, using standard 5-mm or Shigemi 5-mm tubes with suscep-
tibility matched to solvent 2H2O-water sample tubes with a 5-mm outer
diameter. The spectra of the peptide at a 2 mM sample concentration were
recorded in 20 mM sodium phosphate buffer at pH 7.2, prepared in 95%
H2O and 5%
2H2O. Two-dimensional NMR spectra were recorded in the
phase-sensitive mode using the States time-proportional phase incremen-
tation (TPPI) method (45). All experiments were carried out using either
the WATERGATE (water suppression by gradient-tailored excitation)
pulse sequence for water suppression (34) or the excitation sculpting wa-
ter suppression (14) to eliminate the solvent signal in a 95:5 H2O-
2H2O
solution. The COSY (correlation spectroscopy), TOCSY (total correlation
spectroscopy), and NOESY (nuclear Overhauser enhancement spectros-
copy) spectra from the two-dimensional experiments were recorded at
several temperatures within the 280- to 310-K range. 2D TOCSY spectra
were recorded using an MLEV-17 spin-lock sequence (2) with mixing
times (m) of 35 and 70 ms. 2D NOESY experiments were recorded using
a m of 100, 200, or 500 ms. The heteronuclear 1H-13C HSQC (heteronu-
clear single-quantum coherence) spectra were recorded at 280 K in the
same conditions. For NMR experiments with -TrCP, the ligand-to-pro-
tein ratio was set to 98:1 (1.6 mM 4P-Nrf2 or 2P-Nrf2 peptide, 17 M
MBP--TrCP protein). Chemical shift assignments referred to internal
standard 3-(trimethylsilyl) propionic acid-2,2,3,3-d4, sodium salt (TSP-
d4). Transferred nuclear Overhauser effect spectroscopy (TRNOESY)
spectra of 4P-Nrf2 or 2P-Nrf2 with -TrCP were recorded using a m of
100, 200, or 500 ms.
1H saturation transfer difference (STD) NMR spectra of the protein-
peptide mixtures were recorded at 500 MHz with 1,024 scans and selective
saturation of protein resonances at 3 ppm (on-resonance frequency)
(30 ppm for reference spectra). At this frequency, no peptide resonances
are found, whereas the significant line width of the protein signals still
allows this protein to be selectively and uniformly saturated and be effi-
ciently used for the STD NMR technique. In order to achieve the desired
selectivity and to avoid side band irradiation, shaped pulses are employed
for the saturation of the protein signals. STD NMR spectra were acquired
using a series of 40 equally spaced 50-ms Gaussian-shaped pulses for se-
lective saturation (total saturation time  2.05 s), with a 1-ms delay be-
tween the pulses. With an attenuation of 50 dB, the radio frequency field
strength for the selective saturation pulses in all the STD NMR experi-
ments was 190 Hz. The irradiation yields full saturation of the protein by
efficient spin diffusion. Subtraction of flame ionization detection (FID)
values with on- and off-resonance protein saturation was achieved by
phase cycling. Relative STD values were calculated by dividing STD signal
intensities by the intensities of the corresponding signals in a one-dimen-
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sional 1H NMR reference spectrum of the same sample recorded with
1,024 scans and similar parameter conditions.
Structure calculations. The calculated distances were incorporated
into a simulated annealing protocol within the program ARIA 2.3 (25).
Details on the three-dimensional structure calculation were presented
elsewhere (36). PyMOL (http://www.pymol.org) was used for the analysis
and presentation of the results of structure determination. The final step
of the work was a docking analysis using Surflex-Dock 2.0 (SYBYL-X 1.2;
Tripos Certara Company, St. Louis, MO).
Immunohistochemistry. Animals were perfused, brains fixed, and
30-m-thick coronal sections obtained as previously described (39). Sec-
tions were treated as reported elsewhere (19) and incubated for 24 h at 4°C
with rabbit anti-GSK-3 (1:500; Cell Signaling). Secondary biotinylated
anti-rabbit antibody was used at a 1:1,000 dilution for 1 h at room tem-
perature (Vector Labs, Burlingame, CA), and sections were subsequently
developed by using an avidin-biotin peroxidase complex system, follow-
ing the manufacturer’s instructions (ABC kit; Vector Labs). Finally, sec-
tions were incubated in Nissl’s solution (0.1% cresyl violet [Sigma-Al-
drich], 2.5 ml 10% acetic acid) at room temperature for 15 min, rinsed in
deionized water for 5 min, dehydrated in graded alcohols, cleared in xy-
lene, and covered with coverslips.
Analysis of mRNA levels. Total RNA was extracted using TRIzol re-
agent according to the manufacturer’s instructions (Invitrogen). Reverse
transcription and quantitative PCR were done as detailed elsewhere (38).
Primer sequences are shown in Table SB of the supplemental material.
Data analysis was based on the CT method with normalization of the
raw data to housekeeping genes (Applied Biosystems). All PCRs were
performed in triplicate.
Image analyses and statistics. Different band intensities (density ar-
bitrary units), corresponding to immunoblot detection of protein sam-
ples, were quantified using MCID software (MCID, Cambridge, United
Kingdom). Student’s t test was used to assess differences between groups;
a P value of0.05 was considered significant. Unless otherwise indicated,
all experiments were performed at least three times with similar results.
The values presented in the graphs are the means for at least three samples.
Results are expressed as means  standard errors of the means (SEM).
RESULTS
The Neh6 domain of Nrf2 binds -TrCP. In order to map the
domain of Nrf2 that interacts with -TrCP, we transfected
HEK293T cells with expression vectors for V5-tagged enhanced
yellow fluorescent protein (EYFP) linked to various mNrf2 dele-
tion mutants (Fig. 1A) and with a truncated version of -TrCP
that contains the WD40 propeller, which participates in recogni-
tion and binding to substrates, but lacks the Fbox domain, which
is required for interaction with cullin1 (-TrCPFbox) (Fig. 1B).
After transfection, the cells were maintained in serum-free me-
FIG 1 Mapping the Nrf2 domain involved in interaction with -TrCP. (A) Diagram showing the general organization of the Neh domains in Nrf2 according to
reference 16 and the EYFP-mNrf2-V5 chimeras used in pulldown assays with N-terminal deletions of mNrf2. Each chimera carries the following residues from
mNrf2: 1, 98 to 579; 2, 280 to 579; 3, 316 to 579; 4, 381 to 579; 5, 464 to 579. Black boxes indicate the positions of Ser/Thr clusters that might be
phosphorylated by GSK-3 (for details, see Fig. SA in the supplemental material). (B) Ribbon diagram of the E3 ligase adaptor-TrCP (modified from protein data
bank ID 1P22 [52]) showing the substrate binding domain (WD40 propeller) in red and the Skp1 binding domain (Fbox) in blue. (C and D) Pulldown assays of
ectopically expressed EYFP-mNrf2-V5 chimeras and-TrCPFbox-HA, which contains only the WD40 domain (residues 170 to 542 of-TrCP2). HEK293T cells
were cotransfected with expression vectors for the indicated EYFP fusion proteins, 1, 2, 3, 4, and 5, and -TrCPFbox. Thereafter, the cells were
maintained in low-serum medium (0.5% fetal calf serum in DMEM) for 16 h and analyzed by coimmunoprecipitation. (C) Immunoblots showing inputs of
ectopically expressed -TrCPFbox-HA and EYFP-mNrf2-V5 proteins with anti-HA and anti-V5 antibodies, respectively. (D) Immunoprecipitation of EYFP-
mNrf2-V5 fusion chimeras with anti-V5 antibody followed by immunoblot with either anti-HA antibody to detect -TrCPFbox-HA or anti-V5 antibody to
detect EYFP-mNrf2-V5 chimeras.
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dium for 16 h, to ensure that GSK-3 retained its activity (42).
Pulldown of V5-tagged EYFP-(1–5)Nrf2 chimeras showed that
those that contained the Neh6 domain (i.e., 1 to 3) could as-
sociate with HA-tagged -TrCPFbox, whereas those that lacked
the Neh6 (i.e., 4 and 5) could not (Fig. 1C and D). These results
indicate that the Neh6 domain of Nrf2 interacts with the GSK-3/
-TrCP axis.
Identification of Ser residues in theNeh6 domain phosphor-
ylated byGSK-3.The fact that Nrf2 contains many putative phos-
phorylation sites (see Fig. SA in the supplemental material) com-
plicates the identification of modified residues. To simplify this
task, we restricted our study to the examination of the Neh6 do-
main. We generated a fusion protein comprising EYFP and resi-
dues 317 to 372 of mouse Nrf2 (EYFP-mNrf2(317–372)-V5) that
contained the putative sites for GSK-3 phosphorylation and
-TrCP binding. This protein migrated as two bands during SDS-
PAGE, and the retarded band was eliminated if cell lysates were
treated with 	-phosphatase (	PPase) prior to electrophoresis, in-
dicating that it was a phosphorylated form of Nrf2 (Fig. 2A, left).
In contrast, mutation of six Ser residues to Ala (residues 335, 338,
342, 347, 351, and 355) in this region (EYFP-mNrf2(317–372)6S/6A-
V5) yielded a protein with only the fast-migrating form, indicat-
ing that at least some of these six serines are involved in phosphor-
ylation and retarded gel mobility (Fig. 2A, left). When EYFP-
mNrf2(317–372)-V5 was expressed together with active GSK-39,
the pattern of mobility was almost unchanged, making the iden-
tification of residues phosphorylated by the kinase by this ap-
proach difficult (Fig. 2A, right). We circumvented this problem by
employing 2D-PAGE (Fig. 2C and D). HEK293T cells were trans-
fected with EYFP-mNrf2(317–372)-V5 under conditions where
GSK-3 activity was modulated. Inactivation of GSK-3 was
achieved by cotransfection of a hypomorphic version of GSK-3
that retains only residual activity, GSK-3Y216F, and incubation
with the GSK-3 inhibitor SB216763 (10M) during the course of
FIG 2 The Neh6 domain is phosphorylated by GSK-3. (A) (Left) HEK293T
cells were transfected with expression vectors for EYFP-mNrf2(317–372)-V5 and
mutant EYFP-mNrf2(317–372)6S/6A-V5. Cell lysates were incubated with 	PPase
as indicated and resolved by one-dimensional SDS-PAGE. (Top) Immunoblot
with anti-V5 antibody; (bottom) immunoblot with anti--actin antibody to
check equal protein loading. (Right) HEK293T cells were cotransfected with
expression vectors for EYFP-mNrf2(317–372)-V5 and mutant EYFP-
mNrf2(317–372)6S/6A-V5 together with either HA-GSK-3Y216F (plus incuba-
tion with SB216763, 10M, 3 h), as a negative control, or constitutively active
HA-GSK-39. (Top) Immunoblot with anti-V5 antibody; (bottom) immu-
noblot with anti-HA antibody. (B) Comparison of mNrf2 sequences from
wild-type and mutant EYFP chimeras examined in panels C to H. (C) 2D-
PAGE analysis of EYFP-mNrf2(317–372)-V5 in the presence of either HA-GSK-
3Y216F (plus incubation with SB216763) or active HA-GSK-39. (D) Same
lysates as in C after treatment with 	PPase. (E to H) 2D gel analysis of mutant
EYFP-mNrf2(317–372)6S/6A-V5 (E), mutant EYFP-mNrf2(317–372)4S/4A-V5 (F),
mutant EYFP-mNrf2(317–372)2SP/2AP-V5 (G), and mutant EYFP-
mNrf2(317–372)2S/2A-V5 (H), in the presence of HA-GSK-3Y216F (plus incuba-
tion with SB216763) or active HA-GSK-39. Filled arrows indicate acidic
spots that result from GSK-3 phosphorylation; empty arrow indicates spots
whose intensity is reduced in the presence of HA-GSK39 as a result of pro-
tein migration toward that acidic spot. (I and J) In vitro GSK-3 kinase assays
on Nrf2-derived substrates. HEK293T cells were transfected with wild-type
and mutant EYFP-Neh6-V5, as indicated. Cell lysates were immunoprecipi-
tated with anti-V5 antibodies and then subjected to phosphorylation with
recombinant GSK-3. (Top) 32P autoradiography. Filled and empty arrow-
heads indicate phosphorylated EYFP-Neh6-V5 and autophosphorylated GSK-
3, respectively. (Bottom) Immunoblots with anti-V5 antibodies showing similar
amounts of immunoprecipitated EYFP-Neh6-V5 proteins per reaction. To ex-
clude the possibility that a contaminating kinase in the reaction mixture might be
responsible for modifying Nrf2, we performed parallel in vitro kinase assays with-
out recombinant GSK-3. (J) Densitometric quantification of 32P autoradiogra-
phy normalized to EYFP-Neh6-V5 densities. Values are means and SEM from
three independent reactions per EYFP-Neh6-V5 mutant.
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the experiment. Activation of this kinase was performed by
cotransfection with active GSK-39. The modified forms of the
fusion protein were resolved by 2D-PAGE and then blotted with
anti-V5 antibody. Cotransfection of EYFP-mNrf2(317–372)-V5
with GSK-3Y216F and incubation with SB216763 (10 M, 3 h)
resolved this chimera into two rows of spots (Fig. 2C). When cell
lysates were preincubated with 	PPase, the protein migrated as
three spots, indicating the presence of posttranslational modifica-
tions of the fluorescent protein that cannot be attributed to phos-
phorylation (40) (Fig. 2D). More importantly, however, when
cells were cotransfected with EYFP-mNrf2(317–372)-V5 and GSK-
39, we observed an increase in the intensity of spots with acidic
pIs and a decrease in the intensity of spots with basic pIs (Fig. 2C)
as a consequence of phosphorylation. To narrow down the puta-
tive sites of phosphorylation in the Neh6 domain of mouse Nrf2,
we analyzed the point mutants shown in Fig. 2B. The mutant
EYFP-mNrf2(317–372)6S/6A-V5 exhibited similar 2D-PAGE mobil-
ity patterns under conditions of GSK-3 inhibition and activa-
tion, indicating that these Ser residues are crucial for phosphory-
lation by GSK-3 (Fig. 2E). When Ser-to-Ala mutations were
restricted to those at positions 335, 338, 342, and 347, the result-
ing EYFP-mNrf2(317–372)4S/4A-V5 protein yielded the same 2D-
PAGE pattern as EYFP-mNrf2(317–372)6S/6A-V5, indicating that
Ser351 and Ser355 are not phosphorylated by GSK-3 (Fig. 2F). A
mutant with both Ser335 and Ser338 changed to Ala (EYFP-
mNrf2(317–372)2S/2A-V5) presented an enrichment of the most
acidic spot (Fig. 2G, filled arrow) and a decrease in the most basic
spot (Fig. 2G, empty arrow) induced by GSK-39. This chimeric
mutant indicates that GSK-3 can induce phosphorylation of ei-
ther Ser342 or Ser347 or both. Finally, 2D-PAGE examination of a
mutant with Ser342 and Ser347 replaced with Ala (EYFP-
mNrf2(317–372)2SP/2AP-V5) yielded a new pattern of minor spots
with acidic pIs that were enhanced in the presence of GSK-39 (Fig.
2H). Therefore, GSK-3 phosphorylated Ser335 and Ser338, although
the faint intensity of the acidic spots suggests that optimal phosphor-
ylation by GSK-3 requires intact Ser342 and Ser347 residues.
In order to exclude indirect GSK-3 regulation of Nrf2 phos-
phodegron, we performed GSK-3 in vitro kinase assays. EYFP-
Neh6-V5 versions were obtained by immunoprecipitation from
transiently transfected HEK293T cells. These substrates were sub-
jected to enzymatic kinase reactions with recombinant GSK-3.
As shown in Fig. 2I and J, GSK-3 phosphorylated EYFP-Neh6-
V5, but a clear reduction of phosphate incorporation was ob-
served for EYFP-Neh62S/2A-V5 and EYFP-Neh62SP/2AP-V5. Ac-
cording to the previous 2D results, GSK-3 did not phosphorylate
EYFP-Neh64S/4A-V5 and EYFP-Neh66S/6A-V5 mutants. Taken to-
gether, these results indicate that GSK-3 participates in the phos-
phorylation of Ser335, Ser338, Ser342, and Ser347.
Identification of phosphoserines in Neh6 that interact with
-TrCP. We used NMR with two phosphopeptides derived from
human Nrf2, 4P-hNrf2 and 2P-hNrf2, to identify residues in the
Neh6 domain that are bound to -TrCP. Human Nrf2 is longer
than mouse Nrf2, and the Neh6 domain is displaced by 9 residues
despite the fact that the amino acid sequence is identical within the
region studied here (see Fig. SA in the supplemental material).
Therefore, to recapitulate basal and GSK-3-induced phosphory-
lations, the 4P-hNrf2 peptide carried phosphoserines at positions
344, 347, 351, and 356 (equivalent to positions 335, 338, 342, and
347 in mNrf2) whereas the 2P-hNrf2 carried phosphoserines only
at positions 344 and 347, corresponding to GSK-3-induced phos-
phorylations (Fig. 3A). The complete assignment of resonances of
both 2P-hNrf2 and 4P-hNrf2 peptides was established by two-
dimensional 1H, 1H TOCSY, and NOESY experiments. The 13C
signals were assigned using 13C-edited HSQC spectra (51) on sam-
ples containing a natural abundance of 13C. The chemical shifts of
hNrf2 peptides free in solution and in the presence of a recombinant
fusion protein made of maltose-binding protein and the WD40 pro-
peller of-TrCP (MBP--TrCP) were analyzed at 280 K, pH 7.2 (see
Tables SC to SF in the supplemental material). The sequential assign-
ment of 1H resonances was carried out using a classical assignment
strategy (53). The analysis of the Hi-Hi1 NOE cross-peaks re-
vealed the Xi1-Proi bonds to be mainly trans (53). No cis-trans
isomerization was detected across proline amide bonds.
The amide signal shift temperature coefficients [(NH)/T,
in ppb K1] were derived for all backbone amide protons in both
peptides (Fig. 3B). For the residues involved in intramolecular
hydrogen-bonding networks or hidden in the solvent-protected
structural core, low absolute values of this coefficient are expected
compared with the range of values measured for random-coil pep-
tides (3). The region between Asn340 and pSer347, and particularly
Gly345, gave the lowest values, between 7 and 4 ppb K1, and
can be considered to be at least partially protected from external
water molecules. Therefore, the similar pattern observed for this
region in 2P-hNrf2 and 4P-hNrf2 peptides reveals that they pos-
sess similar structures. In the presence of -TrCP (Fig. 3C), the
highest chemical-shift variations () were found roughly in the
same region (344pSGIpSLN349) of both 2P-hNrf2 and 4P-hNrf2
peptides and in pSer351 and pSer356 of 4P-hNrf2 peptide.
To further characterize the amino acids of Nrf2 involved in the
interaction with -TrCP, we used saturation transfer difference
(STD) NMR experiments, as they have been used successfully to
characterize the interaction of -TrCP with substrates such as
Vpu (5),-catenin (30), IB (35), and ATF-4 (36). We observed
Nrf2 signals in the STD spectrum at 280 K, which indicated bind-
ing of -TrCP to the peptides (Fig. 3D). The amide protons of
pSer344 and pSer347 of 2P-hNrf2 and 4P-hNrf2 peptides partici-
pated in this interaction, showing more than 80% relative STD
intensities. Other residues in this region, such as Ile346 and Leu348,
exhibited close to 80% relative STD intensities, suggesting that
they also participate in binding through hydrophobic interac-
tions. In 4P-hNrf2, pSer351 and pSer356 also displayed a high in-
tensity in the STD spectrum. To determine the specificity of these
interactions we repeated the STD experiment for 4P-hNrf2 at 293
K. At this higher temperature, the STD intensity was decreased
(Fig. 3E), indicating dissociation of the complex. To take into
account the STD signal reduction and to allow a better under-
standing of the temperature effect, a global reduction factor of
0.85 was applied for STD intensities at 293 K. The intensities at the
N and C termini of 4P-hNrf2 remained very similar at both tem-
peratures, with mean values of about 50 to 60%. However, the
interactions between Asn340 and Ser360 were reduced at 293 K, but
pSer344, Ile346, and pSer347 retained high STD values. These results
suggest that the residues in the pSGIpS region are essential for the
contacts of both 4P-hNrf2 and 2P-hNrf2 peptides with -TrCP.
Interestingly, the interactions of pSer351 and pSer356 in 4P-hNrf2
were reduced at 293 K (Fig. 3E). These results indicate the impor-
tance of pSer344 and pSer347 in binding to -TrCP, while pSer351
and pSer356 appear to be involved mainly in weak interactions.
Molecular structure of the interactionbetween the phospho-
degron inNrf2 and-TrCP.We sought to elucidate the structure
Degradation of Nrf2 by GSK-3/-TrCP
September 2012 Volume 32 Number 17 mcb.asm.org 3491
FIG 3 Structure analysis of 2P-hNrf2 and 4P-hNrf2. (A) Sequence of 2P-hNrf2 and 4P-hNrf2 phosphopeptides from human Nrf2; for reference with regard to
amino acid positions, the mouse Nrf2 sequence is also shown. In addition, the human -catenin sequence is included for comparison. (B) Temperature
coefficients of the amide proton chemical shifts (ppb K1) for the 2P-hNrf2 and 4P-hNrf2 peptides at pH 7.2 plotted against the residue number. (C) Chemical
shift differences for the NH resonances of the 2P-hNrf2 and 4P-hNrf2 peptides free in buffer solution and in the presence of MBP--TrCP at 280 K and pH 7.2,
plotted against the residue number. (D) Relative STD intensities for 2P-hNrf2 and 4P-hNrf2 peptides. The integral values of the largest signal for the 2P-hNrf2
peptide (pSer347 HN proton) and for the 4P-hNrf2 peptide (pSer344 HN proton) were set to 100%. The relative degree of saturation for the individual protons
normalized to the largest signal was used to compare the STD effect. (E) Effect of temperature (280 K or 293 K) on the relative STD intensities for 4P-hNrf2. The
integral value of the largest signal of the 4P-Nrf2 (pSer344 HN proton) was set to 100% at 280 K. A correction factor of 0.85 was applied to STD values obtained
at 293 K.
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of the complex formed between 2P-hNrf2 and purified MBP--
TrCP by using distance restraints derived from TRNOE spectra at
100- and 200-ms mixing times at 280 K. Of a total of 218 TRNOE
cross-peaks, 108 were translated into unambiguous restraints. Us-
ing the ARIA 2.3 software, 50 structures of 2P-hNrf2 bound to
-TrCP were generated, and their superimposition onto the
DpSGIpS motif of the five lowest-energy structures is displayed in
Fig. 4A. The presence of the phosphorylated serines in the peptide
induces a turn conformation also found in other -TrCP sub-
strates (37). The backbone average root mean square difference
(RMSD) value for the DpSGIpS motif is 1.2  0.6 Å.
A model for the phospho-Nrf2/-TrCP complex was based on
docking calculations starting from the lowest-energy bound struc-
ture that was obtained from the TRNOE NMR experiment. Due to
the high degree of flexibility, Surflex-Dock (17) calculations
were limited to 10 residues centered on the interaction motif
341DSDpSGIpSLNT350. The previously reported three-dimen-
sional crystal structure of human -TrCP in complex with a 10-
residue -catenin peptide (PDB ID code 1P22) (52) was used as
the starting structure for the docking calculations. We obtained 32
configurations of docking conformers. The lowest-energy dock-
ing conformer of the DSDpSGIpSLNT sequence was superim-
posed with the lowest-energy TRNOE bound structure on the
DpSGIpS sequence (Fig. 4B). The backbone RMSD values were
1.9  0.6 Å (DSDpSGIpSLNT) and 1.1  0.4 Å (DpSGIpS). The
turn motif is preserved in both structures, but the position of the
phosphate groups changes. In contrast to the Nrf2-bound struc-
ture, we found that the phosphate groups of pSer344 and pSer347 in
the docked structure adopt a lower-energy conformation that op-
timizes the interaction with the surface of -TrCP. We superim-
posed the seven configurations of docking conformers with the
lowest scores (Fig. 4C) and found a good fit for the pSGI fragment
and Leu348, while the side chain of pSer347 was more flexible. The
backbone RMSD value for the DpSGIpS motif is 0.4 0.2 Å, and
that for the sequence with the 10 residues is 0.9  0.5 Å. The
lowest-energy structure of the complex is shown in a Dreiding
model (Fig. 4D). The amino acids of -TrCP that participate in
hydrogen bonding with Nrf2 are in green. Seven of 10 hydrogen
bonds involve the DpSGI motif, and the remaining three involve
Asn349. The carbonyl and carboxyl groups of Asp343 make two H
bonds with the εNH2 group of Lys
365 of -TrCP. The phosphate
group of pSer344 makes two H bonds with the εNH group of Arg285
and the OH of Ser325 of -TrCP. The carbonyl group of Gly345
forms an H bond with the εNH of Arg474 of-TrCP. The carbonyl
group of Ile346 makes H bonds with the εNH of Arg474 and the OH
of Tyr438 of -TrCP. The 
-carbonyl group of Asn349 forms H
bonds with the εNH of Arg431 and the OH of Ser448 of -TrCP.
Finally, the 
NH2 of Asn
349 makes one H bond with the carbonyl
group of Gly408 of-TrCP. It is possible that pSer347 could form H
bonds or ionic interactions with either the εNH groups of Arg521
or Arg431 of -TrCP, but these contacts were not found in the
lowest-energy structure.
In addition to H bonds, hydrophobic contacts were observed
(Fig. 4E). The side chain of Ile346 is stabilized in the hydrophobic
pocket made by the aromatic rings of Phe523 and Tyr271 and the
guanidinium group of Arg521 of -TrCP. The side chain of Leu348
is stabilized in the hydrophobic central channel involving contacts
with the side chains of Leu351, Asn394, Ala434, and Arg474 on the
WD40 propeller of -TrCP. All these contacts participate in the
stability of the 2P-hNrf2/-TrCP complex.
Ser residues in the Neh6 phosphodegron are necessary for
the interaction with-TrCP. The contribution of individual res-
idues to the association between Nrf2 and -TrCP was examined
using a pulldown assay. In the first set of experiments, HEK293T
cells were cotransfected with expression vectors for Flag-tagged
-TrCP and either GSK-3Y216F as a filling control vector plus
SB216763 or constitutively active GSK-39. The cells were
also cotransfected with a Keap1-insensitive form of Nrf2,
mNrf2ETGE-V5, having either an intact Neh6 (wild type [wt])
or Ser-to-Ala mutations at position 335 (S335A), position 338
(S338A), positions 335 and 338 (2S/2A), or positions 335, 338,
342, and 347 (4S/4A), as indicated in Fig. 5A. Cells were serum
starved for 16 h and kept in the presence of the proteasome
inhibitor MG132 (40 M) for the last 3 h of incubation. Nrf2
with an intact Neh6 domain associated with -TrCP, and this
interaction was enhanced in the presence of active GSK-39.
In contrast, mutations of Ser335, Ser338 or both in mNrf2 were
sufficient to abolish this interaction. These results are consis-
tent with the NMR data.
To further analyze the impact of Ser335 and Ser338 in GSK-3-
mediated regulation of Nrf2, we performed complementation ex-
periments in Nrf2-null MEFs subjected to luciferase assays. MEFs
were transfected with an ARE-driven luciferase reporter construct
(ARE-Luc) and pTK-Renilla as an internal control. In addition,
cells were cotransfected with HA-tagged GSK-3Y216F or active
GSK-39 and increasing amounts of Nrf2-V5, Nrf22S/2A-V5, and
Nrf24S/4A-V5 mutants, as indicated in Fig. 5B. Active GSK-39
attenuated the transactivating capacity of wild-type Nrf2. In con-
trast, Nrf24S/4A was insensitive to GSK-3 regulation. Interest-
ingly, Nrf22S/2A showed only partial modulation by GSK-3.
Overall, these results indicate that GSK-3 activation inhibits Nrf2
function at least through the phosphorylation of Ser335 and Ser338
within the -TrCP interaction motif.
In a second set of experiments, we explored the contribution of
some Arg residues in the WD40 propeller of -TrCP to the dock-
ing of Nrf2. Figure SB in the supplemental material shows the
interaction of Flag-tagged -TrCP with replacements of Arg285,
Arg410, Arg431, Arg474, or Arg521 by Glu with transfected V5-tagged
Nrf2. To assess the relevance of this interaction with endogenous
Nrf2 in the context of GSK-3 activity, HEK293T cells were cotrans-
fected with HA-GSK-3Y216F (and incubated with SB216763) or HA-
GSK-39 and wild-type and the-TrCP point mutants as indicated
in Fig. 5C. Cells were serum starved for 16 h and maintained in 40M
MG132 for the last 3 h. Endogenous Nrf2 associated with Flag--
TrCP, and this interaction was reinforced in the presence of active
GSK-39. Similarly,-TrCPR410E and-TrCPR431E mutants associ-
ated with Nrf2, and the association was also increased in the presence
of GSK-39. In contrast, the mutation of Arg285, Arg474, or Arg521
abrogated the association of Nrf2 with-TrCP. These results are con-
sistent with our docking model based on the NMR data.
In vivo effect of GSK-3 on Nrf2 activity. We analyzed Nrf2
protein levels in mice subjected to five intraperitoneal injections
of the GSK-3 inhibitor SB216763. After 6 h, liver and hippocampal
extracts (Fig. 6A and B) exhibited increased Nrf2 protein levels
comparable to those of mice treated with SFN for 1 h. As a control,
SB216763 also increased -catenin levels (Fig. 6C). As an alterna-
tive approach, we also analyzed Nrf2 function in the hippocampi
of transgenic mice with a conditional neuron-specific depletion of
GSK-3 (Cre). Immunohistochemistry and immunoblotting
revealed a strong reduction in GSK-3 inCre mice compared to
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control mice (Cre) (Fig. 6D and F). Quantitative determination
of mRNA levels indicated a reduction of GSK-3 transcripts to
about 20% relative to control mice, but GSK-3 mRNA levels
were unaffected (Fig. 6E). While GSK-3 protein levels were re-
duced to about 25% in Cre mice, Keap1 and -TrCP levels re-
mained similar (Fig. 6G). In contrast, Nrf2 protein levels were
increased in the hippocampi of Cre mice relative to those in
controlCre mice (Fig. 6F and G). Moreover, both protein (Fig.
7A and B) and mRNA (Fig. 7C) levels of the phase 2 enzymes
HO-1, GSTM5, GCLM, GCLC, and NQO1 were increased in
GSK-3-deficient hippocampi.
The functional impact of the GSK-3-mediated regulation of
Nrf2 was further analyzed in the hippocampi of these mice. As
shown in Fig. 7D, E, and F, hippocampi fromCre mice exhibited
higher levels of reduced glutathione and lower contents of GSSG
than those from Cre mice. Also, Cre mice presented lower
levels of DNPH (Fig. 7G) and MDA (Fig. 7H) than Cre mice,
indicating a reduction in carbonylated proteins and peroxidated
lipids, respectively. These results demonstrate that interruption of
the GSK-3/-TrCP ubiquitination pathway at the level of GSK-3
results in upregulation of Nrf2 and its target genes in vivo, increas-
ing the cellular antioxidant capacity.
DISCUSSION
Nrf2 can be regulated by cell signaling pathways, but the mecha-
nisms involved are not understood. Herein, we describe a Keap1-
independent mechanism by which Nrf2 is repressed that is based
on its interaction with the SCF ubiquitin ligase adaptor -TrCP.
The binding of -TrCP to Nrf2 involves the formation of a phos-
phodegron in the Neh6 domain of this transcription factor that is
catalyzed by GSK-3, and it is therefore apparent that the process is
strongly influenced by signaling via PI3K and mTOR. Moreover,
this mechanism is likely to be perturbed in a number of major
diseases such as cancer, Alzheimer’s disease, and diabetes mellitus.
Mammalian Nrf2 comprises approximately 600 amino acids,
of which more than 100 are serine, threonine, and tyrosine (see
Fig. SA in the supplemental material). The fact that Nrf2 is an
unstable protein that contains many putative phosphorylation
sites complicates the identification of phosphorylation events that
might control its activity. To date, mass spectroscopy studies have
identified phosphorylation sites that appear to have only a rela-
tively minor role in the function of Nrf2. In order to map the
sites in Nrf2 that are phosphorylated by GSK-3, we employed a
reductionist approach that incorporated the following three strat-
egies: (i) creation of an EYFP-Neh6 fusion protein (EYFP-
mNrf2(317–372)) in which the region of interest in Nrf2 was re-
stricted to 56 residues; (ii) site-directed mutagenesis of critical
residues in Neh6; (iii) use of 2D-PAGE to increase the resolution
of phosphorylated and nonphosphorylated proteins. This ap-
proach allowed us to detect two rows of electrophoretically dis-
tinct protein spots. The faster-migrating lower row of spots rep-
resented a posttranslational modification in the fluorescent
protein that is not related to Nrf2, since it was observed in non-
chimeric EGFP (40). The slower-migrating upper row of electro-
phoretic spots correlated with phosphorylation of Neh6, because
it disappeared when cell lysates were treated with 	PPase. The
identification of the slower-migrating bands as phosphorylated
protein is also supported by the fact that when cells were cotrans-
fected with vectors for EYFP-mNrf2(317–372)-V5 and the constitu-
tively active GSK-39 kinase, at least two additional acidic spots
FIG 4 TRNOE-derived structures of the 2P-hNrf2 peptide bound to -TrCP
and analysis of the docking interactions. (A) Of 50 TRNOE-derived structures,
the five lowest-energy conformations are shown. Superimpositions are shown
on the DpSGIpS motif. (B) Nrf2 docked structure (light green) superimposed
on the TRNOE bound structure (dark green) on the DpSGIpS motif. Phos-
phoserine residues are labeled in red in the docked structure and black in the
TRNOE structure. (C) The seven lowest-score configurations that are representa-
tive of the bound structures of Nrf2. The superimposition was made on the DpS-
GIpS motif. (D and E) Structure of the complex of -TrCP with the best docking
conformation of Nrf2 deduced from the NMR data. -TrCP is shown in surface
representation. (D) -TrCP residues that participate in hydrophilic intermolecu-
lar interactions including Arg285, Ser325, Lys365, Gly408, Arg431, Tyr438, Ser448, and
Arg474 (green). H bonds are shown with dashed yellow lines. (E) Amino acids of
-TrCP and Nrf2 that participate in hydrophobic intermolecular interactions.
The hydrophobic cluster located at the entrance of the central channel of-TrCP
(red), interacts with the side chain of Leu348 (green dots). A second hydrophobic
cluster (yellow) interacts with the side chain of Ile346 (green dots).
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FIG 5 Identification of critical residues for Nrf2 docking onto -TrCP. (A) HEK293T cells were cotransfected with Flag-tagged -TrCP, HA-tagged GSK-
3Y216F (plus incubation with SB216763), and GSK-39, as indicated, plus V5-tagged mouse Nrf2ETGE with either a wild-type Neh6 domain (wt) or mutations
of Ser335 to Ala (S335A), Ser338 to Ala (S338A), Ser335 and Ser338 to Ala (2S/2A), or Ser335, Ser338, Ser342, and Ser347 to Ala (4S/4A). Cells were maintained in low
serum for 16 h and treated with 40 M MG132 for the last 3 h before pulldown of protein with anti-V5 antibodies. Lysates from only V5- or HA-transfected
HEK293T were incubated with anti-V5 antibodies and G protein to control unspecific binding. (B) Nrf2-null MEFs were cotransfected with ARE-Luc,
pTK-Renilla as control vector, HA-tagged GSK-3Y216F, or GSK-39, as indicated, and increasing amounts of Nrf2-V5, Nrf22S/2A-V5, or Nrf24S/4A-V5. After 48
h, luciferase activity was determined. Values are means SEM from three independent samples. (C) Association of endogenous Nrf2 with Flag-tagged wild-type
and mutant -TrCPs. HEK293T cells were transfected with the Flag--TrCP constructs and HA-tagged GSK-3Y216F (plus incubation with SB216763) or
GSK-39. After 16 h in low-serum medium, cells were treated for 3 h with 40M MG132 and then immunoprecipitated with anti-Flag antibody. Samples from
cells transfected with empty vector (mock) were included to control unspecific binding.
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were observed in the upper row of polypeptides that coincided
with a reduced intensity of the most basic spot. Taken together,
these results indicate that active GSK-3 increased the abundance
of phosphorylated EYFP-mNrf2-V5. These spots were not ob-
served when cells were transfected with a kinase-deficient mutant
that retains partial activity (GSK-3Y216F) (7) as a filling control
vector and then incubated in the presence of SB216763 to ensure
inactivation of GSK-3.
Analysis of EYFP-mNrf2(317–372)-V5 mutants by 2D-PAGE in-
dicated that Ser342 and Ser347 in mouse Nrf2, which are situated N
terminally to Pro residues, are partially phosphorylated under
conditions of GSK-3 inactivation (cotransfection of HA-GSK-
3Y216F together with incubation with SB216763, 10 M, 3 h),
suggesting that, in addition to GSK-3, other Pro-directed Ser/Thr
kinases might participate in their modification. It is interesting
that the double mutant lacking both Ser342 and Ser347 was still
phosphorylated by GSK-3, although to a lesser extent and with a
somewhat distorted pattern of spots. This result is consistent with
a role for GSK-3 in phosphorylation of Ser335 and Ser338 within the
DpSGIpS phosphodegron. Also, the fact that the most abundant
spots in this mutant correspond to the unphosphorylated protein
suggests that GSK-3 is more effective at phosphorylating this
degron when Ser342 and Ser347 have already been phosphorylated.
Indeed, it is known that GSK-3 exhibits preference for substrates
that have been previously phosphorylated in the consensus se-
quence (S/T)X1– 4p(S/T), where X is any amino acid and p(S/T) is
a Ser/Thr residue that has been previously phosphorylated by
some other “priming” kinase (23). In this regard, the GSK-3 phos-
phorylated sequence of Nrf2 is most similar to that of the human
erythropoietin receptor (SGIS) and human YAP (SGLS), which
also have a smaller spacing of two residues. Nrf2 and EPO R share
the same sequence, while Nrf2 and YAP differ in that a Leu is
changed to Ile. We are currently seeking to identify the putative
kinases that “prime” Ser342 and Ser347 in mouse Nrf2 for subse-
quent modification by GSK-3.
The E3 ligase substrate adaptor-TrCP targets proteins such as
Snail, IB, IB, IKε, WEE1, CDC25A, CDC25B, -catenin,
PDC4, REST, ATF4, PRL-R, IFNR, p63, GHR, Bora, STAT1, Gli2,
Gli3, and Xom for ubiquitination and proteasomal degradation
(1, 9, 20, 24, 32, 33, 49, 50, 55, 56). Many of these proteins are
implicated in cell proliferation, and it is tempting to speculate that
Nrf2 activity is linked to proliferative signals through the GSK-3/
-TrCP axis. Thus, GSK-3 is inhibited by several kinases during
cell proliferation, and this should result in upregulation of Nrf2,
which would in turn afford protection against increased levels of
reactive oxygen species that are generated during cell cycle pro-
gression.
Our NMR studies indicate that the phosphodegron of Nrf2 is
likely to possess a high degree of structure with a turn conforma-
tion which is found also in other substrates of -TrCP (37). Our
FIG 6 Pharmacological and genetic inhibition of GSK-3 increases Nrf2 protein levels. Mice were intraperitoneally injected with five doses of 10 mg/kg SB216367
or with vehicle at 1-h intervals. As a positive control, mice were injected with a single dose of 50 mg/kg SFN. (A) (Top) Immunoblots showing Nrf2 protein levels
in liver and hippocampus. The filled arrowhead indicates Nrf2; the empty arrowhead indicates an unspecific band observed with the anti-mouse Nrf2 antibody.
(Middle) Immunoblots showing -catenin protein levels in liver and hippocampus. (Bottom) Immunoblots for -actin in liver and hippocampus, with similar
protein amounts in all lanes. (B and C) Densitometric quantification of protein levels from representative blots like those in panel A normalized to -actin. (D)
Immunohistochemistry of 30-m-thick hippocampal sections from control mice (Cre), with normal GSK-3 levels, and neuron-specific GSK-3 knockout
mice (Cre). (Top) Anti-GSK-3 antibody staining and Nissl counterstaining. (Bottom) Higher magnification of the CA1 regions. (E) mRNA levels in
hippocampi of GSK-3 and GSK-3 in Cre and Cre mice, determined by qRT-PCR. (F) Immunoblots showing protein levels of GSK-3, Nrf2, Keap1,
-TrCP, and -actin. (G) Densitometric quantification of protein levels from representative blots like those in panel F, normalized to -actin levels. In panels B,
C, E, and G, values are means  SEM for six animals per group. Student’s t test was applied to determine the significance of biochemical differences among
groups. Asterisks denote significant differences between genotypes or treatments (P 0.05).
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data suggest that the DpSGIpSLN motif that adopts the turn struc-
ture and contains phosphoserines pSer344 and pSer347 that play a
specific role in the interaction. In contrast, the adjacent pSer351
and pSer356 residues may not be so important. This interpretation
is consistent with the fact that in other substrates recognized by
-TrCP, GSK-3 phosphorylates a cluster of Ser/Thr residues in the
target protein to give the consensus sequence DpSGX1– 4pS, which
is then recognized by -TrCP through its WD40 domain (8, 44).
We hypothesize that three structural determinants stabilize the
interaction of Nrf2 with-TrCP. First, the phosphate group of the
N-terminal phosphoserine makes H bonds and ionic interaction
with Arg285 and Ser325 of -TrCP. Second, a hydrophobic residue
close to the N-terminal phosphoserine Ile346 interacts with the
hydrophobic pocket formed by Phe523, Tyr271, and Arg521 of
-TrCP. Third, the interaction of a hydrophobic residue with the
central channel of -TrCP, Leu348, should be preserved to allow
the stabilization of the C-terminal phosphoserine with Arg431 or
Arg521 of -TrCP.
As an additional confirmation of our NMR data, we analyzed
the association of mNrf2 and-TrCP mutants in pulldown assays.
Indeed, mutation of Ser335 and Ser338 of mNrf2 (equivalent to
Ser344 and Ser347 of hNrf2) was enough to lose the association with
-TrCP. Moreover, Arg285, Arg474, and Arg521 of the WD40 do-
main of -TrCP were required for docking because when they
were mutated to Glu, the association between Nrf2 and -TrCP
diminished substantially. These observations reinforce our inter-
pretation of NMR data indicating a relevant role of these three
residues in stabilization of docking: Arg258 with pSer344, Arg474
with Gly345 and Ile346, and Arg521 with Ile346 and possibly with
pSer347.
FIG 7 GSK-3 deficiency results in increased expression of Nrf2-target genes and antioxidant capacity. (A) Immunoblots showing protein levels of five enzymes
regulated by Nrf2 (heme oxygenase 1 [HO-1], glutathione S-transferase M5 [GSTM5], 
-glutamyl cysteine ligase modulatory subunit [GCLM], 
-glutamyl
cysteine ligase catalytic subunit [GCLC], and NADPH quinone oxidoreductase [NQO1]). (B) Densitometric quantification of protein levels from representative
blots like those in panel A. (C) mRNA levels of HO-1, GSTM5, GCLM, GCLC, and NQO1, by qRT-PCR. (D) Levels of reduced glutathione (GSH). (E) Levels of
oxidized glutathione (GSSG). (F) GSH/GSSG ratio. (G) Protein carbonyl content as determined by DNPH levels. (H) Thiobarbituric acid-reactive substances
(TBARs) representing mostly MDA. Values are means SEM (n 3). *, P 0.05.
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The functional relevance of the control of Nrf2 by GSK-3/-
TrCP was addressed in vivo by injecting intraperitoneally the
GSK3 inhibitor SB216763 or by using mice with a targeted dele-
tion of GSK-3 in neurons. Depletion of GSK-3 resulted in in-
creased Nrf2 protein levels, which correlated with increased Nrf2-
regulated gene products as well as increased levels of GSH and
lower levels of carbonylated protein and lipid peroxides. These
observations suggest the relevance of the GSK-3/-TrCP axis in
sensitization to oxidant damage. In fact, we have reported that
GSK-3 blocks the protective effect of Nrf2 in a kainic acid-based
model of excitotoxicity in hippocampus (41) and against H2O2-
induced neuronal damage (42). Because GSK-3 has a tremen-
dous impact on many aspects of cell physiology, metabolism, dif-
ferentiation, and proliferation, a more comprehensive vision of
the Nrf2 function and regulation mechanisms will be achieved
only when Nrf2 is analyzed as a downstream target of GSK-3.
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